Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 clinical trial of CF-370 for treating Pseudomonas aeruginosa infections

Next Previous
X
Search
Trial Profile

A Phase 1 clinical trial of CF-370 for treating Pseudomonas aeruginosa infections

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CF 370 (Primary)
  • Indications Nosocomial pneumonia; Pseudomonal infections; Ventilator associated pneumonia
  • Focus Adverse reactions; First in man
  • Sponsors ContraFect

    • Most Recent Events

    • 16 Oct 2023 According to a ContraFect media release, company announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study.
    • 18 Sep 2023 According to a ContraFect media release, the company announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The FDA will review this application and determine the acceptability of the data before CF-370 begins this first clinical trial, which could be as early as Q4 2023.
    • 28 Aug 2023 According to a ContraFect media release, Garrett Nichols, MD, Interim Chief Medical Officer of company, will discuss upcoming IND submission for CF-370 at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top